JeremyW.RuponMD

Physician

Dr. Rupon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3401 Civic Center Blvd
# Chca
Philadelphia, PA 19104
Phone+1 215-590-1000

Fax+1 215-590-4183

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2010 - 2013
Massachusetts General HospitalResidency, Pediatrics, 2007 - 2010
Virginia Commonwealth University School of MedicineClass of 2007

PubMed

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec.
Debra D Pittman, Charles Carrieri, Holly Soares, John McKay, Charles Y Tan
Thrombosis and Haemostasis. 2024-10-01
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
Adam Cuker, Kaan Kavakli, Laurent Frenzel, Jiaan-Der Wang, Jan Astermark
The New England Journal of Medicine. 2024-09-26
5 citations
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington
Blood. 2024-02-29

Abstracts/Posters

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
Jeremy Rupon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020